meta
|
evidence
oncology
Living systematic review and meta-analysis
locally advanced NSCLC - maintenance (M)
laNSCLC - M - all population
1
laNSCLC - M - EGFR mutant
immune chekpoint inhibitors
anti-PD-(L)1
durvalumab based treatment
durvalumab alone